McGill University looking into weight loss and diabetes medications

A new study from McGill University is looking into other uses for some weight loss and diabetes medications.

The study conducted by researchers at McGill University and the Lady Davis Institute for Medical Research at the Jewish General Hospital looked at Ozempic and Wegovy and their efficacy compared to alternative treatments, emerging indications, ongoing challenges, and future directions.

Researchers say, “While early concerns regarding pancreatic and thyroid cancer have been largely attenuated by recent evidence, issues such as gallbladder and biliary disorders, psychiatric safety, and perioperative aspiration risk require ongoing investigation.”

Before adding, “Additionally, observations of weight regain after treatment discontinuation and reductions in lean mass highlight the need for long-term, individualized strategies to sustain clinical benefits. The high cost and limited access to these medications raise critical policy and equity challenges.”

Further research will be conducted to look into long-term safety, optimizing combination approaches, and evaluating the broader clinical and economic implications of the drug use.

For more on the study, click here.